Literature DB >> 17072330

Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression.

D S Bassères1, A S Baldwin.   

Abstract

Abundant data support a key role for the transcription factor nuclear factor-kappaB (NF-kappaB) signaling pathway in controlling the initiation and progression of human cancer. NF-kappaB and associated regulatory proteins such as IkappaB kinase (IKK) are activated downstream of many oncoproteins and there is much evidence for the activation of NF-kappaB-dependent target genes in a variety of solid tumors and hematologic malignancies. This review focuses on the mechanisms by which the NF-kappaB pathway is activated in cancer and on the oncogenic functions controlled by activated NF-kappaB. Additionally, the effects of NF-kappaB activation in tumors relative to cancer therapy are also discussed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17072330     DOI: 10.1038/sj.onc.1209942

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  292 in total

1.  Loss of BRMS1 promotes a mesenchymal phenotype through NF-κB-dependent regulation of Twist1.

Authors:  Yuan Liu; Marty W Mayo; Aizhen Xiao; Emily H Hall; Elianna B Amin; Kyuichi Kadota; Prasad S Adusumilli; David R Jones
Journal:  Mol Cell Biol       Date:  2014-11-03       Impact factor: 4.272

2.  Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance.

Authors:  Kazuhiro Tanaka; Ivan Babic; David Nathanson; David Akhavan; Deliang Guo; Beatrice Gini; Julie Dang; Shaojun Zhu; Huijun Yang; Jason De Jesus; Ali Nael Amzajerdi; Yinan Zhang; Christian C Dibble; Hancai Dan; Amanda Rinkenbaugh; William H Yong; Harry V Vinters; Joseph F Gera; Webster K Cavenee; Timothy F Cloughesy; Brendan D Manning; Albert S Baldwin; Paul S Mischel
Journal:  Cancer Discov       Date:  2011-09-13       Impact factor: 39.397

3.  Inhibition of NFkappaB and pancreatic cancer cell and tumor growth by curcumin is dependent on specificity protein down-regulation.

Authors:  Indira Jutooru; Gayathri Chadalapaka; Ping Lei; Stephen Safe
Journal:  J Biol Chem       Date:  2010-06-09       Impact factor: 5.157

4.  LBH-589 (panobinostat) potentiates fludarabine anti-leukemic activity through a JNK- and XIAP-dependent mechanism.

Authors:  Roberto Rosato; Stefanie Hock; Paul Dent; Yun Dai; Steven Grant
Journal:  Leuk Res       Date:  2011-11-08       Impact factor: 3.156

Review 5.  NF-κB addiction and its role in cancer: 'one size does not fit all'.

Authors:  M M Chaturvedi; B Sung; V R Yadav; R Kannappan; B B Aggarwal
Journal:  Oncogene       Date:  2010-12-20       Impact factor: 9.867

6.  NFKBIA deletion in glioblastomas.

Authors:  Markus Bredel; Denise M Scholtens; Ajay K Yadav; Angel A Alvarez; Jaclyn J Renfrow; James P Chandler; Irene L Y Yu; Maria S Carro; Fangping Dai; Michael J Tagge; Roberto Ferrarese; Claudia Bredel; Heidi S Phillips; Paul J Lukac; Pierre A Robe; Astrid Weyerbrock; Hannes Vogel; Steven Dubner; Bret Mobley; Xiaolin He; Adrienne C Scheck; Branimir I Sikic; Kenneth D Aldape; Arnab Chakravarti; Griffith R Harsh
Journal:  N Engl J Med       Date:  2010-12-22       Impact factor: 91.245

7.  Blocking IKKα expression inhibits prostate cancer invasiveness.

Authors:  Rubi Mahato; Bin Qin; Kun Cheng
Journal:  Pharm Res       Date:  2010-12-30       Impact factor: 4.200

8.  Nuclear factor-kappaB signaling and ezrin are essential for L1-mediated metastasis of colon cancer cells.

Authors:  Nancy Gavert; Amir Ben-Shmuel; Vance Lemmon; Thomas Brabletz; Avri Ben-Ze'ev
Journal:  J Cell Sci       Date:  2010-05-25       Impact factor: 5.285

9.  cIAP2 represses IKKα/β-mediated activation of MDM2 to prevent p53 degradation.

Authors:  Rosanna Lau; Min Ying Niu; M A Christine Pratt
Journal:  Cell Cycle       Date:  2012-10-03       Impact factor: 4.534

10.  Inhibitors of NF-kappaB reverse cellular invasion and target gene upregulation in an experimental model of aggressive oral squamous cell carcinoma.

Authors:  Jeff Johnson; Zonggao Shi; Yueying Liu; M Sharon Stack
Journal:  Oral Oncol       Date:  2014-02-28       Impact factor: 5.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.